CibusCBUS
CBUS
About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Employees: 159
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
211% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 9
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
16% more funds holding
Funds holding: 57 [Q3] → 66 (+9) [Q4]
1.59% more ownership
Funds ownership: 34.16% [Q3] → 35.75% (+1.59%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
10% less capital invested
Capital invested by funds: $29.2M [Q3] → $26.3M (-$2.87M) [Q4]
68% less call options, than puts
Call options by funds: $13K | Put options by funds: $40K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
884%
upside
Avg. target
$22
1,075%
upside
High target
$25
1,266%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Amit Dayal 25% 1-year accuracy 30 / 121 met price target | 1,266%upside $25 | Buy Reiterated | 21 Mar 2025 |
Canaccord Genuity Austin Moeller 18% 1-year accuracy 10 / 56 met price target | 884%upside $18 | Buy Maintained | 22 Jan 2025 |
Financial journalist opinion
Based on 5 articles about CBUS published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Cibus, Inc. (CBUS) Q4 2024 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Carlo Broos - Interim Chief Financial Officer Peter Beetham - Co-Founder, President and COO, Interim CEO Greg Gocal - Co-Founder and Chief Scientific Officer and Executive Vice President Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Sameer Joshi - H. C. Wainwright Matthew Venezia - Alliance Global Partners Operator Good afternoon, and welcome to the Cibus Fourth Quarter 2024 Results Conference Call.
Neutral
GlobeNewsWire
1 week ago
Cibus Reports Fourth Quarter Financial Results and Provides Business Update
A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting within the state
Neutral
GlobeNewsWire
2 weeks ago
Cibus Welcomes the European Union's Progress as Legislation for New Genomic Techniques to Boost Innovation and Sustainability Moves Forward
Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security Proposed legislation identifies a ‘conventional-like' category of NGT-1 products that would be regulated as conventional varieties, bringing EU regulation closer to that of other global trading partners The agreement on the Council's negotiating mandate allows its presidency to start negotiations with the European Parliament on the final text of the regulation SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, welcomes significant progress in the regulation of New Genomic Techniques (NGTs) in the European Union (EU). On Friday 14th March, EU member states endorsed the EU Council's (the “Council”) negotiating mandate on the regulation of plants obtained by NGTs.
Neutral
GlobeNewsWire
3 weeks ago
Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.
Neutral
GlobeNewsWire
4 weeks ago
Cibus' Achieves Another Milestone for a Durable White Mold (Sclerotinia) Resistance Trait in Canola
Initial bioassay data for Cibus' third mode of action for white mold (Sclerotinia) resistance trait in canola shows promising results in controlled environment assessment
Neutral
GlobeNewsWire
1 month ago
Cibus Announces Leadership Change and CEO Succession Plan
SAN DIEGO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced key leadership changes pursuant to the Company's succession planning strategy. The Board has accepted Rory Riggs' resignation as the Company's Chief Executive Officer. Peter Beetham, the Company's President and Chief Operating Officer, also will serve as the Company's Interim Chief Executive Officer. Dr. Beetham is a co-founder of Cibus Global with Mr. Riggs and with Greg Gocal, who will remain the Company's Chief Scientific Officer. Mr. Riggs will remain Chairman of the Board of Directors. Dr. Beetham also will continue as a director.
Neutral
GlobeNewsWire
1 month ago
Cibus Announces Important Update to Rice Gene Editing Conversion Rates
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today issued a correction relating to the rice conversion rates previously disclosed in its January 16, 2025 press release. The Company has concluded that the gene editing conversion rates of 10-25% in Rice have not been reconfirmed based upon subsequent experiments and high variability in the conversion rate data.
Neutral
GlobeNewsWire
2 months ago
Cibus to Participate in the Sidoti Micro Cap Conference
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the Sidoti Micro Cap Conference.
Neutral
GlobeNewsWire
2 months ago
Cibus, Inc. Announces $22.6 Million Registered Direct Offering Priced Above Nasdaq's Minimum Price in Accordance with Nasdaq Rules
SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced it has entered into securities purchase agreements with existing investors of the Company, including institutional and strategic investors, as well as with the Company's CEO, Rory Riggs, for the purchase and sale of 9,040,000 shares of its Class A Common Stock (inclusive of pre-funded warrants to purchase shares of Class A Common Stock, in lieu of common stock), and warrants to purchase up to an aggregate of 9,040,000 shares of Class A Common Stock, at a combined purchase price per share (and accompanying warrant) of $2.50 per share ($2.4999 in respect of the pre-funded warrants (and accompanying warrant)), pursuant to a registered direct offering priced above Nasdaq's Minimum Price in accordance with Nasdaq rules. The warrants will be exercisable upon stockholder approval at a price of $2.50 per share, and will expire five years following the date of stockholder approval. Following stockholder approval, the warrants will be redeemable, at the Company's option, at a redemption price of $0.0001 per warrant following the satisfaction of certain conditions, including (i) the Company's announcement of an operational soybean platform and (ii) the closing price of the Class A Common Stock equaling or exceeding $5.00 per share for fifteen consecutive trading days.
Neutral
GlobeNewsWire
3 months ago
Cibus, Albaugh LLC and RTDC Company Limited Affirm Collaboration to Enable Commercialization of Cibus' First Gene Edited Weed Management Solution for U.S. Rice Growers
Cibus' Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S.
Charts implemented using Lightweight Charts™